Detalhe da pesquisa
1.
Financial toxicity of withdrawn poly (ADP-ribose) polymerase inhibitor indications for ovarian cancer.
Value Health;
2024 Jun 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38871026
2.
Association of body mass index with early age at diagnosis of endometrial intraepithelial neoplasia.
Gynecol Oncol;
175: 15-19, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37290247
3.
High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.
Gynecol Oncol;
179: 97-105, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37956617
4.
Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort.
Am J Obstet Gynecol;
224(3): 278.e1-278.e14, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32835719
5.
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
Gynecol Oncol;
159(2): 483-490, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32863036
6.
National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
Int J Gynecol Cancer;
30(8): 1195-1202, 2020 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32616627
7.
Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes.
Gynecol Oncol;
154(2): 405-410, 2019 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31208738
8.
Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.
Gynecol Oncol;
150(3): 451-459, 2018 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29961559
9.
Financial toxicity: An adverse effect worthy of a black box warning?
Gynecol Oncol;
156(2): 263-264, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32046838
10.
Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention.
Gynecol Oncol;
138(3): 694-9, 2015 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26072441
11.
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Gynecol Oncol;
139(2): 275-82, 2015 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26348313
12.
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway.
J Pharm Policy Pract;
17(1): 2351003, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38841118
13.
Towards value-based universal Lynch syndrome identification in endometrial cancer patients.
Gynecol Oncol;
143(3): 451-452, 2016 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27865420
14.
Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications.
J Control Release;
339: 521-530, 2021 11 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34648891
15.
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.
Gynecol Oncol;
119(1): 38-42, 2010 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20609464
16.
U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Obstet Gynecol;
133(4): 795-802, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30870286
17.
Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis.
Obstet Gynecol;
128(4): 747-753, 2016 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27607867